A Study to Evaluate Cenerimod in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

December 1, 2016

Study Completion Date

December 1, 2016

Conditions

Healthy Subjects

Interventions

DRUG

Cenerimod

Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod

Trial Locations (1)

PRA Health Science, Groningen

All Listed Sponsors

lead

Viatris Innovation GmbH

INDUSTRY

NCT02914223 - A Study to Evaluate Cenerimod in Healthy Male Subjects | Biotech Hunter | Biotech Hunter